Buy $MRK - NRPicks Feb 07

Merck & Co, Inc. provides healthcare solutions worldwide. The company offers treatments for cardiovascular disease, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal infections, fungal infections, insomnia and inflammatory diseases; neuromuscular blocking agents; cholesterol-modifying drugs; and vaginal contraceptive and antibacterial products.
Merck is one of the companies that had been selected to develop the vaccine; however, it is still a company with a very high level team of workers and successful products. In terms of its finances, its debt is average relative to industry-competitors, plus it generates enough cash to be able to meet those obligations.

Fundamentals:
- Growth
- 6% estimated growth in net earnings for the next 3 years.
- ROE 50.5% VS 17% industry.

Technicals:
- Price level below SMA 250-200-150
- Williams R% at -78% levels
- RSI (36) Oversold
-1.5% average upside during the month

A correction of 11% was presented from JANUARY 12 to FEBRUARY 5, which stopped at $75.45 support. The correction was presented because the company abandoned the development of the vaccine against COVID, from the support the stock has shown a change of trend. Finally, the technical indicators are favorable and give us a buy signal.